Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Letermovir (Prevymis) is indicated for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT), as well as in adult kidney transplant recipients at high risk.
• Two systematic review/meta-analysis studies were reviewed, focusing on the use of Prevymis for the prevention of CMV infection and disease, particularly among specific populations such as HSCT and high-risk kidney transplant recipients.
• The drug has demonstrated efficacy in preventing clinically significant CMV infection when compared to placebo or preemptive therapy. It significantly reduced the odds of CMV reactivation, clinically significant CMV infection, and overall mortality rates after transplantation according to pooled estimates from 48 studies.
• While direct safety data was limited within these summaries, a favorable safety profile can be inferred from its effectiveness outcomes, including substantial reductions in infections and mortality rates when compared with traditional preemptive therapy.
• Both studies emphasized Letermovir's value specifically among allo-HSCT recipient populations who are highly susceptible to severe consequences from a potential CMV infection.
• Despite being indicated also for high-risk kidney transplant patients, there is a need for more targeted research focusing on this subgroup since most available evidence primarily focuses on allo-HSCT recipients.